CClinicalTrials.gg
CompletedNCT02440139Updated Nov 4, 2021Results posted

Evaluation of Computer-Aided Lung Nodule Detection Software in Thoracic CT for Riverain Technologies LLC

An interventional study of ClearRead CT Insight in Lung Cancer, sponsored by Virginia Polytechnic Institute and State University. Completed at 1 site in United States. Open to participants aged 55 Years to 77 Years. Per ClinicalTrials.gov, last updated 2021-11-04.

Sponsored by Virginia Polytechnic Institute and State University · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
55 Years to 77 Years
Sex
All
01

Study summary

STUDY DESIGN:

This is a retrospective, multi-reader, multi-case, (MRMC) randomized reader study.

OBJECTIVE:

Primary: The primary objective of this clinical study is to prove that a user aided with ClearRead CT InSight (CRCTI) is superior to the unaided reader for detecting actionable lung nodules.

Secondary: The secondary objective of this clinical study is to prove that the reader's reading time is not significantly increased when aided with CRCTI.

NUMBER OF SUBJECTS:

Retrospective CT studies from approximately 300 patients will be included in the study. Approximately 100 true positive cases and 200 normal cases.

NUMBER OF READERS:

A reader study with at least ten (10) participating radiologists (US Board Certified) will be conducted.

PRIMARY ENDPOINTS:

Scores given by the radiologists with and without ClearRead CT Insight will be recorded and compared to the true status of the study-cases. The frequency of the scores for each method (Unaided, Aided) will be tabulated and LROC curves constructed along with sensitivity, specificity, PPV, NPV and clinical actions. Additionally, machine nodule detection rate and false positives per patient on normal cases will be measured.

PATIENT POPULATION :

The study will target approximately one hundred (100) patients whose CT nodules were shown to be cancer and two hundred (200) normal patients. The patient population will be consistent with the national lung cancer screening protocols.

Read the detailed description

A reader study with at least ten (10) participating radiologists will be conducted. A localized receiver operating characteristic curve will be used to evaluate radiologists' diagnostic performance (in terms of the trade-off between the sensitivity and specificity when the decision criteria changes) in the detection of lung nodules on lung CTs with and without the usage of the ClearRead CT Insight (CRCTI) system. The time needed for the review and interpretation of each case will also be recorded.

An initial (baseline) interpretation will be made by each of the radiologists based on the Lung CT in its original form. At a minimum of one month later, each radiologists will again interpret the same images viewing the pair of CRCTI CT series: Two sets of CT images (standard with CADe marks and processed with vessel suppression will be presented on either one large monitor or two adjacent monitors.

During the baseline reading the radiologist will mark the location of the actionable nodules and assign a score. The radiologist will also indicate the recommended method of follow-up (Contrast CT, PET-CT, CT Follow-up, Biopsy).

During the second reading session (concurrent read), the radiologist will be presented with a standard appearing CT with computer-aided detection (CADe) marks placed and the vessel suppressed same slice with the vessel suppressed view (right image). The second image, vessel suppressed, will be grayed out until the radiologist move the mouse to the second panel. The radiologist will mark locations. These may or may not correspond to the locations of the CAD markers. As before, the radiologist will assign a level of suspicious to each mark and indicate the need, if any, of an additional diagnostic action (CT Follow-up, Contrast CT, PET-CT, or Biopsy).

Based on the levels of suspicion for each nodule and the associated likelihood ratings, LROC curves will be constructed for both the baseline and the concurrent reads and the significance of any difference will be calculated. The recommendations for further action (CT Follow-up, Contrast CT, PET-CT, or Biopsy) will be used to calculate sensitivity and specificity, PPV and NPV.

Number and types of cases:

Retrospective lung CT image series from approximately 300 patients will be included in the study. Approximately one hundred (100) of the patients will have pathology confirmed cancers and approximately two hundred (200) of the patients will be CTs associated with normal patients. Also included as nodule images are those where the actionable nodule was not acted on at that time, but was detected and acted on based on a subsequent CT. These are the prior images where the nodule can be identified and its location is the same as on the "current" image confirmed by the radiologist expert panel (using a majority of three as the decision criterion).

The selected sample, randomly selected from a larger pool of CT cases will be enriched in the following way:

  1. Lung nodules (cancers in this study) will be tumor size T1a (20 mm or less). The proportion of nodules 20 mm or less may be increased since this is where the investigators expect the major impact of this software to be.
  2. Non-Solid (ground glass) nodules will be added to the sample (based on availability) to determine the performance of the system on non-solid nodules. For this group, to have sufficient cases, the investigators may have to include benign (non-malignant) non-solid nodules.
  3. In this project, the investigators will perform a Machine Test of the ClearRead CT Insight algorithm followed by a reader performance evaluation study. Riverain will provide a system configured with the operating point set to be used for the reader studies and a configuration for an "open" system to be used for machine testing and FROC generation.

Arm 1: a baseline read (no secondary content) and Arm 2: concurrent, CAD augmented read.

  1. st Arm: Do baseline (measure time, readers score regions according to action and suspiciousness) - mark all locations of concern
  2. nd Arm: Concurrent read (measure time, readers score regions according to action and suspiciousness) - mark all locations of concern

The primary study hypothesis is that the adjunctive use of ClearRead CT Insight is superior to use of standard lung CT images alone, as measured by the area under the LROC curve.

STATISTICAL ANALYSES Accuracy

To evaluate the hypothesis of superiority in terms of improvement in accuracy for ClearRead CT Insight vs. unaided, a mixed effects model (DBM) will be implemented (similar to the model outlined in Dorfman, Berbaum and Metz, 1997), where variance components will be included to account for reader, case, reader by case, reader by modality, case by modality and reader by case by modality. However, it is anticipated that the three-way interaction will be inestimable and will subsequently be dropped from the statistical model. Specifically, the hypothesis to test for superiority of ClearRead CT Insight vs. unaided is:

H0: AUCunaided - AUCClearRead CT Insight ≥ 0.0 vs. HA: AUCunaided - AUCClearRead CT Insight \< 0

The AUC of the LROC is the primary endpoint to evaluate accuracy and the test of interest will be a two-sided 95% confidence interval on the effect of modality (i.e. ClearRead CT Insight minus unaided). Significance will be concluded if the upper bound of the two-sided 95% confidence interval does not include zero. If the null hypothesis (H0) is rejected, the alternative hypothesis (HA) is accepted and the superiority of using the ClearRead CT Insight system will be established.

Time

The second co-primary objective is to evaluate reduction in time spent per image for ClearRead CT Insight vs. unaided. Specifically, the hypothesis to test for superiority of ClearRead CT Insight vs. unaided is:

H0= Tunaided - TClearRead CT Insight ≤ 0 vs. HA= Tunaided - TClearRead CT Insight > 0

To evaluate the hypothesis of non-inferiority in terms of improved read time for ClearRead CT Insight vs. unaided, a mixed effects model will be implemented (similar to the model outlined in Dorfman, Berbaum and Metz, 1992), where variance components will be included to account for reader, case, reader by case, reader by modality, case by modality and reader by case by modality. However, it is anticipated that the three-way interaction will be inestimable and will subsequently be dropped from the statistical model.

The read times will be tested using a two-sided 95% confidence interval on the effect of modality (i.e. ClearRead minus unaided). Significance will be concluded if the upper bound of the two-sided 95% confidence interval does not include zero.

With either analysis, the use of the mixed model could be modified to employ a bootstrap sampling approach if the model assumptions of the DBM method have been violated. The upper 95 % confidence limit for the difference in the areas under the curves would be calculated using 10,000 bootstraps in the MultiReader MultiCase (MRMC) ROC method.

POWER AND SAMPLE SIZE

The power to detect differences in the AUC of the LROC curve for the proposed statistical analysis using the current design baseline, i.e. 300 cases, each corresponding image read by 10 readers, was assessed through a simulation study. Specifically, the model outlined above was used to simulate 500 datasets across a range of effect sizes, where power was defined as the proportion of datasets that yielded a significant p-value for testing the fixed effect of modality. The method of Dorfman, Berbaum and Metz, 1992 (DBM) was implemented utilizing statistical mixed model theory with jackknife estimates.

These simulations required assumptions regarding the magnitude of the variance components associated with the different random effects. As a pilot study to obtain estimates of variance components was not conducted, variance component estimates from Riverain study SoftView 510(k) (Record # BSSI-PR-09-00006) that uses a similar technology as the proposed ClearRead CT Insight device were used in all power simulations. Please note that the variance components were scaled by the total variance to represent the proportion of total variance explained by each component. All power estimates are dependent upon the appropriateness of the assumed variance components.

02

Conditions studied

  • Lung Cancer
03

In context

Lead sponsor

Virginia Polytechnic Institute and State University is the lead sponsor of 124 studies on the registry; 27 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
55 Years to 77 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

A thoracic CT case that is associated or with a feature of the following:

  1. Asymptomatic patients age 55 - 77 with history of smoking
  2. Primary Lung Cancer
  3. Biopsy Proven (LuRADS 5) with radiology report
  4. Screen detected event plus 1 prior CT. 2 year of prior CTs is preferred, if available.
  5. \<= 3mm slice spacing, no gaps
  6. Use standard reconstruction kernels
  7. Maximum of 5 nodules per image
  8. Nodules must be 5-20mm in size
  9. With or without contrast

Exclusion criteria

Exclusion Criteria:

Thoracic CT cases that meet the following exclusion criteria will not be collected for use during clinical testing.

  1. No Acute pneumothorax
  2. Both lungs must be fully visible within the field of view
  3. Apices cannot be cropped
  4. No excessive motion artifacts
  5. Symptomatic patients with co-morbidities
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
12 participants (actual)

Study arms

  • No intervention
    Arm 1

    Participating radiologists will perform clinical reading on \~300 cases. They will mark all locations of concern (clinically actionable nodules) on conventional thoracic CT images. Computer will measure time, readers score regions according to action and suspiciousness.

  • Active comparator
    Arm 2

    Participating radiologists will perform clinical reading on \~300 cases. They will mark all locations of concern (clinically actionable nodules) on thoracic CT images aided by ClearRead CT Insight software as the intervention. Computer will measure time, readers score regions according to action and suspiciousness.

    Device: ClearRead CT Insight

Interventions

  • DeviceClearRead CT Insight

    During the second reading session (concurrent read), the radiologist will be presented with a standard appearing CT with CADe marks placed and the vessel suppressed same slice with the vessel suppressed view as the intervention. The second image, vessel suppressed, will be grayed out until the radiologist move the mouse to the second panel. The radiologist will mark locations. These may or may not correspond to the locations of the CAD markers. As before, the radiologist will assign a level of suspicious to each mark and indicate the need, if any, of an additional diagnostic action (CT Follow-up, Contrast CT, PET-CT, or Biopsy).

06

What researchers measure

Primary outcomes

  1. Comparing the Detection Accuracy, Sensitivity, and Specificity of Clinically Actionable Lung Nodules

    The detection rates in accuracy, sensitivity, and specificity on clinically actionable lung nodules were computed and compared for Aim 1 (baseline) and Arm 2 (study participants were aided with ClearRead CT software) studies.

    Time frame: 4 months

  2. Comparing LROC Curve in the Detection of Clinically Actionable Lung Nodules Among Normal

    The areas under location-specific Receiver Operating Characteristic (LROC) curves were computed and compared for Aim 1 (baseline) and Aim 2 (study participants were aided with ClearRead CT software).

    Time frame: 4 months

Secondary outcomes

  1. Average Reading Time Per Case

    The average reading times per reader per case were computed and comapred in both Aim 1 and Arm 2 (study participants were aided with ClearRead CT software) studies.

    Time frame: 4 months

07

Results

Posted Oct 4, 2021
Limitations and caveats
This study only used a relatively low number of thoracic CT cases read by 12 radiologists. The study cases were mainly collected from the National Lung Screen Trial (NLST) lung cancer screening program. In addition, the study suffered from readers' lack of learning time of using the AI software.

Participant flow

12 radiologists were invited to participate in a two-arms reader study.

Participant flow — Overall Study
MilestoneArm 1
Started12
Completed12
Not completed0

Outcome measures

PrimaryComparing the Detection Accuracy, Sensitivity, and Specificity of Clinically Actionable Lung Nodules

The detection rates in accuracy, sensitivity, and specificity on clinically actionable lung nodules were computed and compared for Aim 1 (baseline) and Arm 2 (study participants were aided with ClearRead CT software) studies.

Time frame:
4 months
Reported as:
Count of units · CT-case | nodule
Comparing the Detection Accuracy, Sensitivity, and Specificity of Clinically Actionable Lung Nodules
CT-case | noduleArm 1Arm 2
Detection Accuracy36123735
Detection Sensitivity12831548
Detection Specificity23292187
Statistical analysis
  • Arm 1 vs Arm 2 · Mixed Models Analysis · p = <0.05 · Difference in sensitivity: -0.124 · 95% CI -0.186 to -0.062
PrimaryComparing LROC Curve in the Detection of Clinically Actionable Lung Nodules Among Normal

The areas under location-specific Receiver Operating Characteristic (LROC) curves were computed and compared for Aim 1 (baseline) and Aim 2 (study participants were aided with ClearRead CT software).

Time frame:
4 months
Reported as:
Geometric mean · Probability
Comparing LROC Curve in the Detection of Clinically Actionable Lung Nodules Among Normal
ProbabilityArm 1Arm 2
Comparing LROC Curve in the Detection of Clinically Actionable Lung Nodules Among Normal0.633 (0.594 to 0.672)0.773 (0.734 to 0.812)
Statistical analysis
  • Arm 1 vs Arm 2 · ANOVA · p = <0.05 · Difference in lroc curves: -0.14 · 95% CI -0.209 to -0.071
SecondaryAverage Reading Time Per Case

The average reading times per reader per case were computed and comapred in both Aim 1 and Arm 2 (study participants were aided with ClearRead CT software) studies.

Time frame:
4 months
Reported as:
Mean · Second
Average Reading Time Per Case
SecondArm 1Arm 2
Average Reading Time Per Case98.0 (88.0 to 108.0)132.3 (122.3 to 142.3)

Adverse events

Collected over 4 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 10/12 (0%)0/12 (0%)0/12 (0%)
Arm 20/12 (0%)0/12 (0%)0/12 (0%)

Baseline characteristics

12 US board-certified radiologists were invited to participate in the study. They were 8 males and 4 females.

Age, Categorical
Age, Categorical(Participants)Arm 1: Baseline Study
<=18 years0
Between 18 and 65 years12
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1: Baseline Study
Female4
Male8
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Arm 1: Baseline Study
Region of Enrollment
Region of Enrollment(participants)Arm 1: Baseline Study
United States12
08

Study locations

1 site
  • Arlington Innovation Center: Health Resaerch
    Arlington, Virginia 22203, United States
09

References and documents

Publications

  • Beyer F, Zierott L, Fallenberg EM, Juergens KU, Stoeckel J, Heindel W, Wormanns D. Comparison of sensitivity and reading time for the use of computer-aided detection (CAD) of pulmonary nodules at MDCT as concurrent or second reader. Eur Radiol. 2007 Nov;17(11):2941-7. doi: 10.1007/s00330-007-0667-1. Epub 2007 May 22. PubMed 17929026 ↗
  • Dorfman DD, Berbaum KS, Metz CE. Receiver operating characteristic rating analysis. Generalization to the population of readers and patients with the jackknife method. Invest Radiol. 1992 Sep;27(9):723-31. No abstract available. PubMed 1399456 ↗
  • Foti G, Faccioli N, D'Onofrio M, Contro A, Milazzo T, Pozzi Mucelli R. Evaluation of a method of computer-aided detection (CAD) of pulmonary nodules with computed tomography. Radiol Med. 2010 Sep;115(6):950-61. doi: 10.1007/s11547-010-0556-6. Epub 2010 Jun 23. English, Italian. PubMed 20574707 ↗
  • Matsumoto S, Ohno Y, Aoki T, Yamagata H, Nogami M, Matsumoto K, Yamashita Y, Sugimura K. Computer-aided detection of lung nodules on multidetector CT in concurrent-reader and second-reader modes: a comparative study. Eur J Radiol. 2013 Aug;82(8):1332-7. doi: 10.1016/j.ejrad.2013.02.005. Epub 2013 Mar 6. PubMed 23480965 ↗
  • Obuchowski NA. New methodological tools for multiple-reader ROC studies. Radiology. 2007 Apr;243(1):10-2. doi: 10.1148/radiol.2432060387. No abstract available. PubMed 17392244 ↗
  • Obuchowski NA, McClish DK. Sample size determination for diagnostic accuracy studies involving binormal ROC curve indices. Stat Med. 1997 Jul 15;16(13):1529-42. doi: 10.1002/(sici)1097-0258(19970715)16:133.0.co;2-h. PubMed 9249923 ↗

Study documents

  • Protocol and statistical analysis plan · Aug 24, 2017

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 4, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02440139
Lead sponsor
Virginia Polytechnic Institute and State University
Collaborators
Riverain Technologies
Responsible party
ShihChung Ben Lo (Adjunct Professor, Virginia Polytechnic Institute and State University) — Principal investigator
First posted
May 12, 2015
Start date
Apr 2015
Primary completion
Sep 2017
Completion
Mar 2018
Results posted
Oct 4, 2021
Last update
Nov 4, 2021

Study contacts

Matthew T Freedman, M.D.
study director · Virginia Polytechnic Institute and State University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion